NCT02429882View on ClinicalTrials.gov

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2015

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Axial Spondyloarthritis
Interventions
DRUG

Brodalumab 210 mg

210 mg brodalumab will be administered subcutaneously

DRUG

Placebo

Placebo will be administered subcutaneously

Trial Locations (5)

16635

Research Site, Duncansville

73103

Research Site, Oklahoma City

85258

Research Site, Scottsdale

R3A 1M3

Research Site, Winnipeg

R3N 0K6

Research Site, Winnipeg

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY